Zingerone Suppresses Tumor Development through Decreasing Cyclin D1 Expression and Inducing Mitotic Arrest

Area of Science:

• Oncology
• Pharmacology
• Molecular Biology

Background:

• Cancer is characterized by uncontrolled cell proliferation due to aberrant cell-cycle protein activity, making complete cures challenging despite chemotherapy.
• Cell-cycle regulators are emerging as critical targets for novel cancer therapies.
• Zingerone, a natural phenolic compound from ginger, possesses diverse pharmacological activities and is considered safe and affordable.

Purpose of the Study:

• To investigate the therapeutic potential of zingerone as an anti-mitotic agent against human neuroblastoma cells.
• To elucidate the molecular mechanisms underlying zingerone's anti-cancer effects.
• To evaluate zingerone's efficacy in a preclinical mouse model of cancer.

Main Methods:

• Human neuroblastoma cells (BE(2)-M17) were treated with zingerone, followed by MTT and colony-formation assays to assess proliferation.
• Immunofluorescence cytochemistry and flow cytometry were used to analyze mitotic cell populations.
• Western blotting and immunohistochemistry were employed to examine key cell-cycle proteins (cyclin D1, caspase-3, PARP-1, p-Histone H3).
• A BALB/c mouse-tumor model was utilized to evaluate in vivo anti-cancer effects.

Main Results:

• Zingerone significantly inhibited cellular viability and survival in human neuroblastoma cells.
• Treatment with zingerone led to an accumulation of mitotic cells, specifically in prometaphase.
• Zingerone decreased cyclin D1 expression and induced the cleavage of caspase-3 and PARP-1, indicating apoptosis induction.
• In vivo studies confirmed decreased cyclin D1 and increased phosphorylated histone H3 in zingerone-treated tumor tissues.

Conclusions:

• Zingerone effectively induces mitotic arrest and inhibits the growth of neuroblastoma cells.
• The anti-cancer mechanism involves the downregulation of cyclin D1 and the activation of apoptotic pathways.
• Zingerone demonstrates significant potential as a therapeutic agent for neuroblastoma and potentially other human cancers.